Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

"Under the new agreement, Regeneron will supply an additional 1.4 million 1,200 mg doses of REGEN-COV to the U.S. government by January 31, 2022, at a cost of $2,100 per dose," a press release ...

Regeneron's billionaire chief executive Leonard Schleifer has said that the drug industry's pricing is ... from Gilead Sciences. Sovaldi cost $1,000 a pill, or $86,000 per course of ...

Regeneron's stock has soared 60% this year, while its CEO has been a member of one of the president's golf clubs. Latest ... That comes out to a cost of about $1,500 per treatment.

Regeneron’s first quarter was marked by a negative market reaction, as revenue and non-GAAP earnings fell short of Wall ...

The World Health Organization added a Regeneron medication to its list of recommended treatments for Covid-19, but also criticized the company's pricing and distribution of the drug.

Regeneron and Sanofi will soon offer a 60 percent discount off the $14,600 list price of cholesterol-lowering drug Praluent to clients of Express Scripts.

The Regeneron Pharmaceuticals company logo is seen on a building at the company's Westchester campus in Tarrytown, New York, U.S. September 17, 2020. Picture taken September 17, 2020.

Regeneron was able to ensure that its donations to CDF were used only to cover cost-sharing for Eylea in an effort to block competitors, Humana claims in the suit.

The US Food and Drug Administration (FDA) has granted accelerated approval for Regeneron Pharmaceuticals’ Lynozyfic ...

Cost of goods sold was $239 million. R&D and SG&A expenses totaled $1.412 billion and $792 million, respectively. Notably, Regeneron’s R&D expenses grew 20% year-over-year.